Behzad Kharabi Masouleh
Overview
Explore the profile of Behzad Kharabi Masouleh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
894
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salimi A, Schemionek-Reinders M, Huber M, Vieri M, Patterson J, Alten J, et al.
J Cell Mol Med
. 2023 Sep;
27(21):3363-3377.
PMID: 37753803
Activating point mutations of the RAS gene act as driver mutations for a subset of precursor-B cell acute lymphoblastic leukaemias (pre-B ALL) and represent an ambitious target for therapeutic approaches....
2.
Shah B, Ghobadi A, Oluwole O, Logan A, Boissel N, Cassaday R, et al.
J Hematol Oncol
. 2022 Dec;
15(1):170.
PMID: 36494725
Background: Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) based...
3.
Wayne A, Huynh V, Hijiya N, Rouce R, Brown P, Krueger J, et al.
Haematologica
. 2022 Oct;
108(3):747-760.
PMID: 36263840
Here we present the 3-year results of ZUMA-4, a phase I/II multicenter study evaluating the safety and efficacy of KTEX19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in...
4.
Maletzke S, Salimi A, Vieri M, Schroeder K, Schemionek M, Kharabi Masouleh B, et al.
PLoS One
. 2022 Oct;
17(10):e0268352.
PMID: 36194587
Acute lymphoblastic leukemia (ALL) is a disease of lymphoid progenitor cells with an often aggressive course and is commonly caused by the BCR-ABL fusion gene t(9;22) in adults. This fusion...
5.
Salimi A, Schroeder K, Schemionek-Reinders M, Vieri M, Maletzke S, Gezer D, et al.
BMC Cancer
. 2022 Jul;
22(1):735.
PMID: 35790913
Background: The therapeutic armamentarium in multiple myeloma has been significantly broadened by proteasome inhibitors, highly efficient means in controlling of multiple myeloma. Despite the developments of therapeutic regimen in treatment...
6.
Shah B, Smith N, Feng C, Jeyakumar S, Castaigne J, Faghmous I, et al.
Adv Ther
. 2022 Jun;
39(8):3678-3695.
PMID: 35727476
Introduction: Despite currently available treatments for adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL), survival outcomes remain poor, highlighting the need for new therapeutic strategies. This study estimates the cost-effectiveness...
7.
Shah B, Ghobadi A, Oluwole O, Logan A, Boissel N, Cassaday R, et al.
Lancet
. 2021 Jun;
398(10299):491-502.
PMID: 34097852
Background: Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia remain poor, underlining the need for...
8.
Vieri M, Preisinger C, Schemionek M, Salimi A, Patterson J, Samali A, et al.
Carcinogenesis
. 2020 Sep;
42(2):272-284.
PMID: 32915195
BCR-ABL1-positive acute lymphoblastic leukemia (ALL) cell survival is dependent on the inositol-requiring enzyme 1 alpha (IRE1α) branch of the unfolded protein response. In the current study, we have focused on...
9.
Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, et al.
Cancer Cell
. 2020 Jan;
37(1):135-136.
PMID: 31935370
No abstract available.
10.
Sun H, Lin D, Guo X, Kharabi Masouleh B, Gery S, Cao Q, et al.
Oncotarget
. 2017 Oct;
8(38):64651.
PMID: 28969101
[This corrects the article DOI: 10.18632/oncotarget.7702.].